Pulse Radiotherapy to Overcome Metastatic Immune System Evasion in Lung Cancer

This phase I study aims to evaluate the safety and effectiveness of adaptive pulsed radiotherapy combined with immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC) resistant to immune checkpoint inhibitors. The primary goal is to assess treatment-related toxicity, while secondary objectives include progression-free survival, overall survival, and quality of life. The study will enroll 32 patients.

Trial Details

NCT ID
NCT06622174
Phase
PHASE1
Sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Pulse radiotherapy
Locations (sample)
  • Montreal, Quebec, Canada|45.50884,-73.58781

Key Eligibility Criteria

  • Participants must be ≥ 18 years old
  • Ability to provide written informed consent
  • Actively receiving PD(L)-1 inhibitors
  • Progressive disease defined as per RECIST criteria 1.1 on CT metrics as a greater than 20% increase in the sum measurement of lesions, non-target u…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →